Niederer Kraft Frey acted as counsel to Idorsia Ltd in its sale of 23,800,000 shares by way of an at-market rights offering. The gross proceeds from the offering of CHF 535.5 million will be used to support the regulatory filing and, if approved, commercial launch of daridorexant, Idorsia’s dual orexin receptor antagonist, and to fund the clinical development of its other late-stage compounds as well as early-stage pipeline assets.
Idorsia successfully completes capital increase with gross proceeds of CHF 535.5m
Deirdre Ní Annracháin
HIGHLIGHT27 October 2020